NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss of $0.10

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) reported Q2 EPS of ($0.10), versus ($4.34) reported last year.

As of June 30, 2022, cash was $24.5 million compared to $27.6 million as of December 31, 2021. They believe that they have sufficient funds and if necessary, the ability to reduce expenditures, to support operations through August 2023. The Company may also seek to reduce certain expenditures if needed to reduce cash consumption in support of operations.

For earnings history and earnings-related data on NRx Pharmaceuticals, Inc. (NRXP) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
• Goldman Sachs Double Upgrades Bradsaude SA (SAUD3:BZ) to Buy